Accession Number:

ADA288508

Title:

Longterm Follow-up of Patients in CSP Number 298 , Treatment of Patients with 'Acquired Immune Deficiency Syndrome (AIDS) and AIDS related Complex'.

Descriptive Note:

Final rept. 1 Apr 91-30 Apr 94,

Corporate Author:

VETERANS ADMINISTRATION MEDICAL CENTER WASHINGTON DC

Personal Author(s):

• Simberkoff, Michael S.
• Hartigan, Pamela M.
• Hamilton, John D.

Report Date:

1994-10-01

Pagination or Media Count:

25.0

Abstract:

To evaluate the benefits of early E vs. Later L ZDV therapy, we enrolled 338 symptomatic HIV patients with CD4 counts of 200-500cmm into a randomized, double-blind trial. Patients were assigned to initial ZDV 1,500 mgday E 168 pts or initial placebo L. 170 The latter were switched to ZDV after progression to AIDS or to a court 200cmm. All pts were offered ZDV 500 mgday following completion of blinded follow-up. Blinded and final follow-up were completed in January 1991 and 1994, respectively. Median follow-up was 52 months. Progressions to AIDS occurred in 67 and 84 pts in the E and L therapy groups, respectively rel. risk, 0.73 95 CI, 0.52- l.01 p 0.054. Death occurred in 74 and 73 pts in the E and L therapy groups, respectively rel. risk, 0.99 95 CI, 0.72-1.37 ns. We conclude that early compared with later ZDV provides marginal protection against progression to AIDS but no survival benefit.

Descriptors:

• *PATIENTS
• *MEDICAL SERVICES
• * PLACEBOS
• *HUMAN IMMUNODEFICIENCY VIRUSES
• RISK
• CLINICAL MEDICINE
• SIGNS AND SYMPTOMS
• LONG RANGE(TIME)
• SURVIVAL(GENERAL)
• DEFICIENCIES
• ILLNESS
• INFECTIOUS DISEASES
• DEATH
• IMMUNITY
• THERAPY*ACQUIRED IMMUNE DEFICIENCY SYNDROME
• PUBLIC HEALTH

Subject Categories:

• Medicine and Medical Research
• Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE